Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis names once-yearly zoledronic acid Aclasta

Executive Summary

Aclasta will be the trade name for Novartis' once-yearly I.V. infusion formulation of zoledronic acid for treatment of Paget's disease. The priority review date on the Aclasta NDA is in March, the company said. Novartis anticipates a 2007 filing of Aclasta in treatment of osteoporosis (1"The Pink Sheet" Nov. 24, 2003, p. 29). Novartis also markets zoledronic acid under the trade name Zometa for treatment of prostate cancer...

You may also be interested in...

Zometa, Aredia May Have Different Jaw Osteonecrosis Risk Profiles

Further study of jaw osteonecrosis risk may differentiate Novartis' bisphosphonates Zometa and Aredia, FDA Division of Oncology Drug Products Director Richard Pazdur suggested

Novartis R&D Portfolio Grows 44% Since 2000; Half Of Projects Are NMEs

Novartis' clinical R&D portfolio has grown 44% over the last four years, with new molecular entities representing about half the drugs in development, Global Pharma Development Head Joerg Reinhardt, PhD, said Nov. 19 during Novartis' R&D day in New York

Deals In Depth: March 2021

BridgeBio Pharma’s affiliate QED Therapeutics granted and Helsinn Group exclusive global rights (excluding Greater China) to the FGFR1-3 inhibitor infigratinib in oncology and all other indications except skeletal dysplasias (including achondroplasia). BridgeBio could see up to $2.45bn in payments from the deal, including over $100m in up-front, regulatory, and launch payments, and the remainder in sales milestones. In the month’s top M&A, Amgen entered into an agreement to acquire fellow public biotech Five Prime Therapeutics for about $1.9bn, gaining Phase III-ready bemarituzumab for frontline advanced gastric or gastroesophageal junction cancer.  





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts